Spinifex Pharmaceuticals Pty Ltd

The University of Queensland

Other

Novartis Ag

Qrxpharma Limited

Uniquest Pty Limited

Maree Therese Smith

Bruce Douglas Wyse

Fraser Ross

Compositions and methods are for inducing, promoting or otherwise facilitating pain relief. More particularly, sub-normovasodilatory doses of nitric oxide donors are used in the therapeutic management of vertebrate animals including humans, for the prevention or alleviation of pain, especially neuropathic pain. In some applications of the method, nitric oxide donors can be administered by any suitable route so as to provide concentrations of NO that are about &#xbd; to 10times those known to induce vasodilation in normal circulations.

Pain-relieving compositions and uses therefor

A method of treatment, reversal and/or symptomatic relief of inflammatory pain, including hyperalgesia, thermal or mechanical allodynia, in vertebrate animals, particularly in human subjects, comprising administering angiotensin II receptor 2 (ATreceptor) antagonists is disclosed. The ATreceptor antagonist may be provided alone or in combination with other compounds such as those that are useful in the control of inflammatory pain.

Method of treatment or prophylaxis of inflammatory pain

The present invention is directed to methods and agents that are useful in the prevention and amelioration of signs and symptoms associated with neuropathic conditions. More particularly, the present invention discloses the use of angiotensin II receptor 2 (ATreceptor) antagonists for the treatment, prophylaxis, reversal and/or symptomatic relief of neuropathic pain, including mechanical hyperalgesia, thermal or mechanical allodynia, diabetic pain and entrapment pain, in vertebrate animals and particularly in human subjects. The ATreceptor antagonists may be provided alone or in combination with other compounds such as those that are useful in the control of neuropathic conditions.

Method of treatment or prophylaxis

This invention discloses compositions and methods for inducing, promoting or otherwise facilitating pain relief. More particularly, the present invention discloses the use of sub-normovasodilatory doses of nitric oxide donors in the therapeutic management of vertebrate animals including humans, for the prevention or alleviation of pain, especially neuropathic pain. According to some embodiments of the present invention, nitric oxide donors are administered by any suitable route so as to provide concentrations of NO that are about &#xbd; to 10of those known to induce vasodilation in normal circulations.

The present invention relates to methods for reducing the risk associated with the administration of opioid analgesics in patients diagnosed or undiagnosed with respiratory illness by administering an analgesic composition comprising a sub-analgesic dosage of a p-opioid agonist selected from the group consisting of morphine, fentanyl, sufentanil, alfentanil, oxymorphone and hydromorphone, or a pharmaceutically acceptable salt thereof, and a sub-analgesic dosage of oxycodone which is a &#x3ba;-opioid agonist or a pharmaceutically acceptable salt thereof.

Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness

An analgesic composition is disclosed comprising a sub-analgesic dosage of a &mgr;-opioid agonist, optionally in the form of a pharmaceutically acceptable salt, and a sub-analgesic dosage of a &kgr;,-opioid agonist, optionally in the form of a pharmaceutically acceptable salt. There is also disclosed a method for producing analgesia in humans and lower animals which comprises administering concurrently to a human or lower animal in need of such treatment an analgesic composition of the invention.

Growing community of inventors

Bardon, Australia

Maree Therese Smith